Physician profile
Ryan D Rainer
NPI 1811916620
$5,129.92
in general payments reported to CMS, 2019-2025
44 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,217 · 2020: $1,332 · 2021: $1,114 · 2022: $616 · 2023: $446 · 2024: $183 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $850.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $562.63 | 2019-2025 | Zepbound, Mounjaro, Amyvid |
| Astrazeneca Pharmaceuticals Lp | $526.27 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $501.66 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $470.78 | 2019-2024 | |
| Pfizer INC. | $466.08 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $283.45 | 2019-2021 | |
| Allergan, INC. | $281.95 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $221.88 | 2019-2023 | Relistor |
| Amgen INC. | $189.61 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $185.16 | 2019-2022 | |
| Glaxosmithkline, LLC. | $169.74 | 2019-2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.10 | 2019-2021 | |
| Genentech USA, INC. | $106.37 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $84.42 | 2019-2021 | |
| Adlon Therapeutics L.P. | $67.86 | 2020-2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Rainer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.